[Federal Register Volume 77, Number 202 (Thursday, October 18, 2012)]
[Notices]
[Page 64142]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-25644]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances, Notice of Application, 
Noramco, Inc.

    Pursuant to Title 21, Code of Federal Regulations (CFR), 
1301.34(a), this is notice that on August 6, 2012, Noramco, Inc., 500 
Swedes Landing Road, Wilmington, Delaware 19801-4417, made application 
by renewal to the Drug Enforcement Administration (DEA) for 
registration as an importer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phenylacetone (8501).......................  II
Opium, raw (9600)..........................  II
Poppy Straw Concentrate (9670).............  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to import raw Opium (9600) and Poppy Straw 
Concentrate (9670) to manufacture other controlled substances. The 
company plans to import Tapentadol (9780) in intermediate form for the 
bulk manufacture of Tapentadol (9780) for distribution to its 
customers. The company plans to import Phenylacetone (8501) in bulk for 
the manufacture of a controlled substance.
    Comments and requests for hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (2007).
    In regard to the non-narcotic raw material, any bulk manufacturer 
who is presently, or is applying to be, registered with DEA to 
manufacture such basic classes of controlled substances listed in 
schedules I or II, which fall under the authority of section 
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than November 19, 2012.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: October 9, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-25644 Filed 10-17-12; 8:45 am]
BILLING CODE 4410-09-P